Jeffrey Cohen, MD
Neurology · Cleveland, OHNPI 1104867118
Payments from drug & device makers
Across 107 payments — averaging $28,929 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.2M
- Biogen$400K
- E.r. Squibb & Sons, L.L.C.$371K
- Sanofi$27K
- Mylan Inc.$18K
- Adamas Pharmaceuticals, Inc.$14K
- plus $62K from 17 others
Across 26 payments — averaging $1423.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$20K
- Bristol Myers Squibb$8K
- Novartis Pharma AG$8K
- F. Hoffmann-la Roche AG$676
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $2,203,682 |
| Biogen | 8 | $399,841 |
| E.r. Squibb & Sons, L.L.C. | 9 | $370,601 |
| Sanofi | 8 | $27,197 |
| Mylan Inc. | 10 | $18,038 |
| Adamas Pharmaceuticals, Inc. | 2 | $14,100 |
| Mallinckrodt Hospital Products Inc. | 3 | $14,043 |
| Mallinckrodt Enterprises LLC | 7 | $12,691 |
| Bristol Myers Squibb | 5 | $8,294 |
| Janssen Global Services, LLC | 7 | $5,890 |
| Legend Biotech USA Inc. | 2 | $3,775 |
| EMD Serono, Inc. | 3 | $3,698 |
| F. Hoffmann-la Roche AG | 5 | $3,472 |
| Merck Kgaa | 1 | $2,650 |
| GSK | 2 | $1,892 |
| AstraZeneca | 1 | $1,880 |
| Hexal AG | 1 | $1,300 |
| Shionogi Inc | 1 | $1,220 |
| Genentech, Inc. | 1 | $900 |
| TG Therapeutics, Inc. | 1 | $127 |
| Pfizer | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Novartis Pharma AG | 1 | $14 |
How this compares
$3,095,377 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Cleveland
- Robert BermelCleveland$6.4M
- Yuebing LiCleveland$1.4M
- Devon ConwayCleveland$1.3M
- Robert FoxCleveland$1.3M
- Glen StevensCleveland$1.1M
- Hubert FernandezCleveland$1.1M
- Hesham AbboudCleveland$1.1M
- Michal GostkowskiCleveland$850K
- Daniel OntanedaCleveland$838K
- Alan LernerCleveland$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.